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Introduction
Priapism is a rare urological emergency that can result in long- 
term erectile dysfunction if prompt presentation and medical 
intervention is not performed. Priapism is a disruption related to 
the usual physiological mechanisms controlling penile tumescence 
and detumescence, leading to a prolonged penile erection that is 
unrelated to sexual stimulation1.
Currently, there are three accepted subtypes: ischemic or low- 
flow priapism, non-ischemic or high-flow priapism, and stuttering 
priapism, also known as recurrent ischemic priapism1–4. For the 
purposes of consistency, the terms ischaemic and non-ischaemic 
are preferred over low flow and high flow, particularly when 
interpreting penile imaging following therapeutic interventions 
and it also ensures that clinicians appreciate the urgency of 
intervention.
The aim of treatment is the immediate resolution of the painful 
erection and the preservation of cavernosal smooth muscle 
function in order to prevent long-term penile shortening and 
refractory erectile dysfunction secondary to cavernosal fibrosis.
There has been very little in the way of new developments in 
priapism, with the majority of novel concepts related to early 
implantation of a penile prosthesis and a better understanding 
of the imaging modalities. Some of these advances will be 
discussed below.
Advances in priapism diagnostics
The clinical history and examination can be supplemented by 
radiological imaging and blood gas analyses from the corpus 
cavernosum, which in most cases will provide a diagnosis and 
differentiation between the different subtypes. Further investi-
gations using urine toxicology, haematological screening, and 
abdominal imaging is performed to investigate an underlying 
cause, although the majority of ischaemic priapism cases are 
likely to be idiopathic (Table 1).
Clinical history
Ischaemic priapism often presents well beyond the four-hour 
time frame commonly used as the time interval in international 
guidelines whereby smooth muscle necrosis within the corpus 
cavernosum commences5.
Non-ischaemic priapism can have a preceding history of blunt 
or penetrating perineal or genital trauma, which may have 
occurred several weeks before the onset of priapism. Penile 
discomfort rather than severe penile pain is often reported by 
patients; however, accurately distinguishing this condition 
from ischaemic priapism, which requires prompt intervention, is 
imperative.
Radiological imaging in priapism
Assessment of blood flow within cavernosal arteries and the 
corpus cavernosum to distinguish ischaemic from non-ischaemic 
priapism subtypes can be performed using colour penile Doppler 
ultrasonography. Impaired blood flow of the distal corpus 
cavernosum and reduced or absent perfusion within the cavern-
osal arteries is seen in ischaemic priapism cases on colour penile 
Doppler imaging. However, if blood has already been aspirated 
from the corpora, interpreting penile Doppler studies can be 
problematic because of the development of abnormal aberrant 
blood flow in sections of the corpus cavernosum6. In non- 
ischaemic priapism, the Doppler studies will demonstrate a 
high velocity throughout the corpus cavernosum and often the 
demonstration of a fistula. A recent study interpreting the Doppler 
waveforms shows that the interpretation is often difficult once 
interventions have been undertaken7.
Blood gas analysis
A more reliable investigation to distinguish between ischaemic 
and non-ischaemic priapism is to aspirate blood from the corpus 
cavernosum for blood gas analysis prior to any other 
intervention8. This will confirm blood with a low pO2 and aci-
dosis if the diagnosis is ischaemic priapism or a normal pO2 and 
normal pH in cases of non-ischaemic priapism (Table 2).
Management of ischaemic priapism
If the duration of priapism is between 4 and 24 hours, the ini-
tial conservative management involves pain management, 
encouraging ejaculation, vigorous physical exercise, and ice 
packs with the aim to induce smooth muscle contraction via 




Idiopathic, haematological dyscrasias (e.g. sickle cell anaemia, thalassemia, and leukaemia), illicit drugs  
(e.g. cocaine and marijuana), medications (e.g. antipsychotics, antidepressants, intracavernosal prostaglandin 
E1 injections, anticoagulants, and alpha blockers), pelvic malignancy, neurological disorders (e.g. spinal cord 
injury), toxic infections (e.g. scorpion sting), and metabolic disorders (e.g. gout, amyloidosis).
Non-ischaemic 
priapism
Trauma to penis/perineum, treatment of ischaemic priapism*.
*The other mechanism for non-ischemic priapism is in the management of low-flow priapism that requires injections. It is often reported that the 
needles themselves can transect or damage cavernosal arteries, thus creating a fistula de novo and converting what was an ischaemic priapism 
into a non-ischaemic scenario.
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sympathomimetic α receptors and thus induce detumescence. 
Failing this, the following steps should be used to manage 
ischaemic priapism:
i) Aspiration and instillation of α agonists into the corpus 
cavernosum
Following a penile block, if aspiration of ischaemic blood fails to 
resolve the priapism, instillation of α-adrenergic agonists (usually 
200 μg of phenylephrine repeated to a maximum of 1,500 μg) 
is the next step. Both aspiration and injection of α-agonists is 
performed via a large bore needle (19G) inserted through the 
glans penis and into the corpora or directly into the penile shaft 
at the 2 or 10 o’clock positions to avoid injuring the neurovascu-
lar bundles. This manoeuvre aims to increase the smooth muscle 
tone of the corpora cavernosa and promote detumescence.
Alternative α-adrenergic agonists include metaraminol and 
adrenaline. High-dose phenylephrine has also been successfully 
utilised in small case series9, although in refractory cases it is 
unlikely to be successful owing to the development of irrevers-
ible smooth muscle dysfunction5,10. Ischaemic blood aspira-
tion alone may remedy the ischaemic priapism in up to-one 
third of cases; therefore, it should always be the first approach 
before administering phenylephrine because of the impair-
ment of smooth muscle contraction by the development of an 
ischaemic microenvironment11,12. Phenylephrine injection should 
be performed with continuous monitoring of blood pressure, 
especially in patients with pre-existing hypertension, as it may 
potentially precipitate a cardiovascular event.
Priapism episodes lasting more than 24 to 36 hours are less 
likely to respond to corporal blood aspiration and instillation of 
α-adrenergic agonists because of the presence of irreversible 
smooth muscle damage. However, it is essential to perform the 
above manoeuvres in all patients presenting with ischaemic 
priapism irrespective of the time of presentation. This is because 
the absolute time point at which permanent smooth muscle 
damage occurs is not clear, although hypoxia, glucopenia, and 
acidosis usually develop within six hours of the commencement 
of ischaemic priapism.
If ischaemic priapism is reversed within 24 hours, there is 
usually a recovery of erectile function in approximately 50% 
of patients, while a duration of more than 36 hours of the pria-
pism episode is invariably associated with a degree of corporal 
fibrosis and erectile dysfunction13. The outcomes in the time period 
of 24 to 36 hours are variable and governed by the degree of 
ischaemia and the amount of reversible smooth muscle function if 
penile detumescence is achieved.
Both in vitro and in vivo studies have shown that hypoxia and 
glucopenia may function as independent factors causing 
cavernosal smooth muscle dysfunction and that irreversible 
histopathological alterations are caused by the combination of 
acidosis, glucopenia, and hypoxia that last for more than four 
hours5.
Histologically, as priapism continues, the corpus cavernosum 
undergoes progressive changes. In cases where priapism is of a 
short duration (less than 12 hours), the tissue consists of minor 
endothelial defects with occasional lymphocytic infiltration but the 
smooth muscle cells remain intact. It is only after 12 to 14 hours 
of ischaemic priapism that the trabecular smooth muscle cells 
show the beginning of focal cytoplasmic transformation, with the 
perinuclear cytoplasm, endoplasmic reticulum, ribosomes, and 
Golgi apparatus exhibiting an increase in size. In the time period 
of 24 to 48 hours, there is widespread endothelial destruction 
and exposure of the basement membrane. In addition to this, the 
smooth muscle cells undergo transformation as well as necrosis. 
Persistent blood stasis for over two days is related to the infil-
tration of the trabecular tissue with inflammatory cells and the 
smooth muscle cells undergoing necrosis or phenotypically 
changing into fibroblast-like cells14.
At the molecular level, decreases in phosphodiesterase type 5 
(PDE-5) and RhoA/Rho kinase, increased levels of adenosine, 
and the presence of acidosis, glucopenia, and hypoxia are all 
likely to contribute to cavernosal smooth muscle dysfunction15.
ii) Management of priapism using surgical shunts
For those patients in whom corporal blood aspiration and instil-
lation of α-adrenergic agonists are ineffective, surgical shunts are 
frequently required. The concept of surgically created shunts is to 
allow the drainage of ischaemic blood from the corpora cavernosa 
to either the corpus spongiosum or the saphenous vein, although 
the older shunts (proximal) described are no longer routinely 
used.
Minimally invasive distal percutaneous shunts such as The 
Winter and Ebbehoj can be used. The Winter shunt 
involves the insertion of a large bore needle or a can-
nula into the glans penis and the distal end of the corpus 
cavernosum. The Ebbehoj procedure entails a stab incision with 
a No. 10 scalpel blade into the corpora cavernosa through the 
glans penis. When percutaneous shunt surgery is unsuccess-
ful, an Al-Ghorab shunt, which is an open corporoglanular shunt 
involving the excision of a segment of tunica albuginea from the 
tip of the corpus cavernosum, has been described.
The most recent shunt techniques aim to allow better communi-
cation between the distal corpora and glans penis. Described as 
a T-shunt, the technique involves the insertion of a No. 10 blade 
through the glans penis into the ipsilateral corpus cavernosum 
followed by a 90-degree rotation laterally away from the urethra 
to create a fistula16. If detumescence is not achieved, the proce-
dure can be redone on the contralateral side (TT shunt technique). 
In cases where TT shunt has failed, a tunnelling manoeuvre may 
be attempted; this technique allows the ischaemic blood to be 







Ischaemic priapism <30 >60 <7.25
Non-ischaemic priapism >90 <40 7.35
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drained from the proximal aspect of the corpora cavernosa. This 
procedure, also known as the corporal snake manoeuvre, uses a 
22 French urethral sound through the previous T-shunt17,18.
Although early reports demonstrate the safety of a distal shunt 
coupled with the tunnelling manoeuvre, with resolution achieved 
in nearly all cases17, a recent series of 45 patients has shown that 
the success of the T shunt and tunnelling manoeuvre is dependent 
on the duration of the priapism19.
iii) Implantation of a penile prosthesis in acute priapism
If aspiration of ischaemic blood from the corpora cavernosa 
followed by repeated instillations of α-adrenergic agonists does 
not induce resolution of the priapism episode, irreversible damage 
to the smooth muscle is likely to have already occurred. Conse-
quently, efforts to re-oxygenate the corpora with shunt surgery, 
even though it could resolve the painful priapism episode, will 
not prevent the onset of refractory erectile dysfunction in the long 
term, which will ultimately require the implantation of a penile 
prosthesis20.
Penile prosthesis implantation, which has been the traditional 
treatment in patients who have developed erectile dysfunction 
following a prolonged priapism, has now been advocated as an 
alternative initial management strategy for prolonged ischaemic 
priapism21,22.
In fact, urgent penile prosthesis implantation in cases of refrac-
tory priapism and cavernosal smooth muscle necrosis reduces the 
painful priapism occurrence, assures the necessary long-term 
rigidity required for sexual intercourse, and stops penile short-
ening and curvature secondary to the development of corporal 
fibrosis, which would otherwise be unavoidable.
Potential overtreatment of patients with no evidence of necro-
sis in the cavernosal smooth muscle is one of the risks associated 
with this approach, and therefore the correct timing of surgery 
is paramount. Although after 24 to 48 hours of a persistent 
erection irreversible smooth muscle necrosis has already devel-
oped, the use of additional imaging modalities and cavernosal 
smooth muscle biopsies aid clinicians in the decision of whether 
or not an early penile prosthesis is suitable or whether a more 
conservative approach can be used with the hope that there is 
cavernosal smooth muscle recovery in the long term. In a 
series of 23 patients, in which the radiological findings have 
been correlated with biopsies from the corpus cavernosum, 
gadolinium-enhanced high-definition magnetic resonance imaging 
(MRI) of the penis demonstrated a sensitivity of 100% when 
utilised in the detection of necrosis of the cavernosal smooth 
muscle23. Therefore, this imaging modality may be extremely 
useful in supporting the clinical decision to proceed with acute 
penile prosthesis implantation rather than adopt a conservative 
policy. Therefore, MRI imaging with diagnostic biopsies aid 
decision making in these difficult cases.
Implantation of a malleable prosthesis is easier in the early 
period (first two weeks) of refractory ischaemic priapism, as 
corporal fibrosis has not been completely established. At a later 
date, the malleable prosthesis can be exchanged for an inflatable 
prosthesis, this also allows upsizing of the cylinders24.
In challenging cases where the corpora are severely fibrosed, 
simultaneous penile prosthesis implantation and corporal 
reconstruction has been shown to offer satisfactory results. 
However, patients must be fully counselled and made aware that 
complication rates are significantly higher in these complex cases 
because of the severe fibrosis25. Several other techniques have 
been described (e.g. multiple corporal incisions, corporal 
excavation, and downsized prosthesis) in order to minimize 
complications and improve surgical outcomes26.
Update on the management of ischaemic and  
non-ischaemic priapism
Daily low-dose PDE-5 inhibitor treatment in a small series of 
patients prevented recurrent priapism while preserving normal 
erectile function. Burnett et al. reported this interesting therapy 
to prevent recurrent ischaemic priapism (stuttering) in a study 
providing evidence to support the role of nitric oxide synthase/
PDE-5 dysregulation as an essential factor in the pathogenesis of 
priapism27.
The presence of oxygenated blood within the corpora and the 
lack of severe penile pain allows non-ischaemic cases to be 
managed conservatively provided that the initial diagnosis is 
accurate. After a conservative treatment approach, which requires 
regular clinical review, has been employed, diagnostic angiog-
raphy combined with super-selective embolization of any fistula 
can be performed if the fistula has not yet closed spontaneously. 
Occasionally, patients can develop fibrosis within the distal 
corpora in long-standing non-ischaemic priapism and therefore 
early intervention with embolization is advocated to prevent 
this. Fibrosis within the distal corpus cavernosum can present 
as distal flaccidity and is best imaged using a penile MRI scan28.
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